On this page
- Quick reference
- Dosage chart and four steps
- Supplies needed
- Peptide Reconstitution Simulator
- Vial and research context
- GHK-Cu 50 mg Dosage Protocol Overview
- GHK-Cu 50 mg Dosage Guide and Dose Calculations
- What the 50 mg Vial Changes
- GHK-Cu Peptide Research Context
- Copper Peptide Skin, Collagen, and Wound Research
- Copper Binding and Proposed Mechanisms
- GHK-Cu Topical Dosage Versus Injectable Protocol
- GHK-Cu Injection Dosage and Measurement Technique
- Storage and Formulation Limits
- Injectable GHK-Cu Safety and Evidence Limits
- GHK-Cu 50 mg Dosage Guide: Reading the Dose
- GHK-Cu Dosing Mistakes and Protocol Checks
- GHK-Cu Peptide Use, Formulations, and Research Terms
- GHK-Cu Side Effects and Research Monitoring
- GHK-Cu 50 mg Dosage FAQ
- References
- Related research, protocols, and guides
GHK-Cu Quick Reference (50 mg Vial)
- Vial contents
- 50 mg GHK-Cu
- Final volume
- 3 mL
- Concentration
- 16.67 mg/mL
- One U-100 unit
- 166.67 mcg in 0.01 mL
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read GHK-Cu Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
GHK-Cu Dosage Chart
Dosing & Reconstitution Guide
Educational guide for reconstitution and common dosing patterns
Standard / Conservative Approach (3 mL = 16.67 mg/mL; 5 days/week)
| Week/Phase | Dose per Injection | Units (per injection) (mL) |
|---|---|---|
| Weeks 1-4 | 1.0 mg (1000 mcg) | 6 units (0.06 mL) |
| Weeks 5-8 | 1.5 mg (1500 mcg) | 9 units (0.09 mL) |
| Weeks 9-12+ | 2.0 mg (2000 mcg) | 12 units (0.12 mL) |
Frequency: Once daily, 5 days per week, progressing from 1.0 mg to 1.5 mg and then 2.0 mg as shown above. At 16.67 mg/mL, those doses equal 6, 9, and 12 U-100 units. Use a U-100 syringe with markings that clearly display every value in the table.
Reconstitution Steps
- Draw 3.0 mL of the protocol-specified sterile diluent with a sterile syringe.
- Add it slowly down the vial wall to reduce foaming.
- Gently swirl or roll until dissolved. Do not shake.
- Label the vial with the 16.67 mg/mL concentration, preparation date, and storage instructions.
Alternative Protocol (3 mL = 16.67 mg/mL; 3 times weekly)
| Week/Phase | Dose per Injection | Units (per injection) (mL) |
|---|---|---|
| Weeks 1-12+ | 2.0 mg (2000 mcg) | 12 units (0.12 mL) |
Frequency: 2.0 mg three times per week, such as Monday, Wednesday, and Friday. At 16.67 mg/mL, each injection equals 12 U-100 units (0.12 mL), for approximately 6 mg per week.
Supplies Needed
Plan based on an 8-16 week protocol. Calculations are shown for both the 5 days/week and 3 times/week schedules.
-
Peptide Vials (GHK-Cu, 50 mg each):
- 5 days/week (1.0-2.0 mg/day):
- 8 weeks (~50 mg total): 1 vial
- 12 weeks (~90 mg total): 2 vials
- 16 weeks (~130 mg total): 3 vials
- 3 times/week (2 mg each):
- 8 weeks (~48 mg total): 1 vial
- 12 weeks (~72 mg total): 2 vials
- 16 weeks (~96 mg total): 2 vials
-
Insulin Syringes (U-100, 29-31 gauge):
- 5 days/week:
- Per week: 5 syringes
- 8 weeks: 40 syringes
- 12 weeks: 60 syringes
- 16 weeks: 80 syringes
- 3 times/week:
- Per week: 3 syringes
- 8 weeks: 24 syringes
- 12 weeks: 36 syringes
- 16 weeks: 48 syringes
-
Sterile or Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for the displayed calculation.
- 1 vial: 3 mL
- 2 vials: 6 mL
- 3 vials: 9 mL
-
Alcohol Swabs: Two administration swabs per injection: one for the vial stopper and one for the injection site.
- 5 days/week:
- Per week: 10 swabs
- 8 weeks: 80 swabs or 1 x 100-count box
- 12 weeks: 120 swabs or 2 x 100-count boxes
- 16 weeks: 160 swabs or 2 x 100-count boxes
- 3 times/week:
- Per week: 6 swabs
- 8 weeks: 48 swabs or 1 x 100-count box
- 12 weeks: 72 swabs or 1 x 100-count box
- 16 weeks: 96 swabs or 1 x 100-count box
Planning note: Peptide and water totals are arithmetic minimums based on the listed schedule. Follow the handling and discard limits for the exact products used.
Peptide Reconstitution Simulator
Practice preparing this vial with the verified strength and final volume from this protocol.
GHK-Cu Vial and Research Context
- Reconstitute: Prepare the 50 mg vial to a final volume of 3.0 mL for a concentration of 16.67 mg/mL.
- Research protocol range: The tables below cover 1.0 mg, 1.5 mg, and 2.0 mg using the standard and alternative research-use schedules.
- Easy measuring: At 16.67 mg/mL, 1 U-100 unit = 0.01 mL = approximately 166.7 mcg.
- Quick conversions: 1.0 mg = 6 units, 1.5 mg = 9 units, and 2.0 mg = 12 units.
GHK-Cu, or glycyl-L-histidyl-L-lysine copper complex, is a naturally occurring copper peptide studied for collagen-related pathways, tissue remodeling, antioxidant defense, and skin repair[7][8]. This educational GHK-Cu dosage protocol presents the same research-use schedule for the 50 mg vial, with calculations adjusted for its concentration.
GHK-Cu 50 mg Dosage Protocol Overview
This GHK-Cu 50 mg dosage page pairs a 50 mg vial with a 3.0 mL final volume. That preparation produces a 16.67 mg/mL concentration and makes each U-100 syringe unit equal to approximately 166.7 mcg. The dosage chart above combines the amount per administration, syringe units, mL, frequency, and phase so every row can be read without a separate calculator.
- Vial strength: 50 mg GHK-Cu.
- Final volume: 3.0 mL after preparation.
- Concentration: 16.67 mg/mL.
- U-100 conversion: 1 unit = 0.01 mL = approximately 166.7 mcg.
- Research boundary: Published human GHK-Cu evidence is predominantly topical or wound-focused; it does not validate a universal injectable GHK-Cu dose.[1][2][5]
GHK-Cu 50 mg Dosage Guide and Dose Calculations
The calculation starts with concentration: 50 mg divided by 3.0 mL equals 16.67 mg/mL. Because a U-100 syringe has 100 volume units per mL, one unit represents 0.01 mL. Multiplying 16.67 mg/mL by 0.01 mL gives approximately 0.1667 mg, or 166.7 mcg, per unit.
- 1.0 mg: 1.0 ÷ 16.67 = 0.06 mL, displayed as 6 U-100 units.
- 1.5 mg: 1.5 ÷ 16.67 = 0.09 mL, displayed as 9 U-100 units.
- 2.0 mg: 2.0 ÷ 16.67 = 0.12 mL, displayed as 12 U-100 units.
These are strength-specific arithmetic conversions for the 50 mg vial. U-100 units are syringe volume markings, not peptide international units, and the vial strength does not independently establish a clinical protocol.
What the 50 mg Vial Changes
A larger vial changes concentration, measurement, and vial yield - not the biological identity of GHK-Cu. At 16.67 mg/mL, the 50 mg vial produces smaller injection volumes for the same milligram amount than a more dilute preparation. It also contains 50 individual 1 mg amounts, about 33 individual 1.5 mg amounts, or 25 individual 2 mg amounts before practical handling or discard limits are considered.
This exact-strength focus separates the page from the broader GHK-Cu dosage family page. Use the 50 mg chart when the vial label and final volume match this page; if either value differs, recalculate concentration before interpreting syringe markings.
GHK-Cu Peptide Research Context
GHK-Cu is the copper complex of glycyl-L-histidyl-L-lysine, a naturally occurring tripeptide. Laboratory and review literature describes interactions with extracellular-matrix remodeling, antioxidant signaling, inflammatory pathways, and gene expression.[7][8] These mechanisms help explain why GHK-Cu research commonly focuses on skin, collagen, wound repair, and tissue remodeling.
Route and formulation matter. Human studies in the reference set examined topical creams, gels, nano-serums, laser-aftercare products, or wound-related applications rather than the subcutaneous calculation schedules shown above.[1][2][3][4][5] The injectable GHK-Cu protocol numbers on this page therefore remain educational research calculations, not a conclusion drawn from those topical trials.
Copper Peptide Skin, Collagen, and Wound Research
Human research has evaluated GHK-Cu-containing topical preparations in diabetic ulcers, cosmetic skin treatment, and post-procedure care. Reported outcomes across these studies include measures related to wound closure, skin quality, collagen, elastin, and wrinkle appearance, but the formulations, study designs, and endpoints are not interchangeable.[1][2][3][4]
A human-skin penetration study provides formulation-specific context for topical delivery, while an animal wound-chamber model offers preclinical evidence for local GHK-Cu exposure.[5][6] Neither source establishes an injectable dose for a 50 mg vial. Their value is in explaining why topical concentration, delivery vehicle, route, and tissue exposure must be kept distinct from syringe calculations.
Copper Binding and Proposed Mechanisms
The GHK portion binds copper ions and forms the GHK-Cu complex. Reviews describe this copper peptide as a signaling molecule associated with tissue remodeling, cellular defense, and changes in gene expression.[7] Experimental work has also examined matrix metalloproteinase regulation, including MMP-2, which participates in extracellular-matrix turnover.[8]
Mechanistic findings are useful for forming research questions, but they do not determine a GHK-Cu injection dosage. A biological pathway, topical result, or preclinical signal cannot by itself establish the safety, frequency, cycle length, or effectiveness of an injectable protocol.
GHK-Cu Topical Dosage Versus Injectable Protocol
Topical GHK-Cu and reconstituted injectable GHK-Cu are different research contexts. A topical serum or gel is characterized by its percentage, vehicle, skin penetration, and application surface. A prepared vial is characterized by milligrams, final mL, mg/mL concentration, and the volume measured in a syringe. Results from one route should not be presented as proof for another.
Regulatory records reinforce the importance of route. The FDA has published separate information involving topical products, compounded bulk substances, and safety-risk considerations for injectable GHK-Cu.[10][11][12] An ongoing clinical trial of topical GHK-Cu gel also remains formulation- and route-specific.[9]
GHK-Cu Injection Dosage and Measurement Technique
Accurate measurement begins by confirming the vial strength, final volume, concentration, and syringe scale before drawing any solution. For this 50 mg vial prepared to 3.0 mL, the relevant concentration is 16.67 mg/mL. A U-100 syringe shows volume markings: 6 units equals 0.06 mL, 9 units equals 0.09 mL, and 12 units equals 0.12 mL.
General subcutaneous technique guidance emphasizes clean preparation, a new sterile syringe, appropriate site selection, site rotation, and immediate sharps disposal.[15][16][17] Those sources support handling practices, not the GHK-Cu dosage schedule itself.
Storage and Formulation Limits
Storage depends on the exact formulation, diluent, sterility, concentration, container, light exposure, and supplier documentation. Label the prepared vial with the compound, 16.67 mg/mL concentration, preparation date, and the applicable storage instructions. Do not infer a universal discard date from the words “50 mg vial” alone.
- Before preparation: Follow the sealed product and lot documentation.
- After preparation: Follow the exact formulation’s validated temperature and light-protection requirements.
- Inspection: Do not use a solution that is cloudy, discolored, or contains unexpected particles.
- Recordkeeping: Record final volume, concentration, preparation date, and disposal date.
Injectable GHK-Cu Safety and Evidence Limits
There is no universally established injectable GHK-Cu clinical protocol for the 50 mg vial in the cited human literature. The page’s dosage chart is an arithmetic presentation of named research-use schedules, while the academic references primarily support the compound’s topical, wound, penetration, mechanism, and regulatory context.
Potential risks depend on route, dose, formulation, sterility, handling, and individual factors. FDA materials specifically identify safety and quality concerns relevant to compounded injectable GHK-Cu, so topical data should not be used to dismiss injectable uncertainty.[10][11] This distinction is central to interpreting GHK-Cu research responsibly.
GHK-Cu 50 mg Dosage Guide: Reading the Dose
This GHK-Cu dosage guide separates three ideas that are often confused: the peptide amount, the liquid volume, and the syringe marking. The dose is the mass of peptide stated in milligrams. The volume is the number of milliliters that contains that dose. The U-100 marking is a convenient way to measure that volume. A 1 mg dose is not “one unit,” and a 12-unit syringe marking is not a 12 mg dose.
For the displayed preparation, each dose can be checked in two ways. Divide the desired peptide dose by 16.67 mg/mL to calculate mL, or divide the desired dose by 0.1667 mg per unit to calculate U-100 units. A 1 mg dose gives approximately 0.06 mL and 6 units. A 1.5 mg dose gives 0.09 mL and 9 units. A 2 mg dose gives 0.12 mL and 12 units. The two methods should agree before a calculation is recorded.
The GHK-Cu dosage depends on the research question and the named protocol, not simply on the amount available in the container. The schedule above states the dose per administration and frequency together. Do not convert a per-administration dose into mg per day or mg daily unless the schedule actually specifies daily administration. Likewise, cycle length and weekly frequency must remain visible when comparing dose calculations.
GHK-Cu Dosing Mistakes and Protocol Checks
Most errors in a GHK-Cu injection dosage calculation come from mixing values that belong to different preparations. The following checks help keep the GHK-Cu dose, concentration, and syringe volume aligned without changing the underlying protocol.
- Using the wrong final volume: This GHK-Cu protocol assumes 3.0 mL. Reconstituted GHK-Cu prepared to a different volume has a different concentration.
- Reading units as milligrams: U-100 units describe volume. Always pair the unit marking with the stated peptide dose.
- Confusing a single dose with a weekly total: A dose per administration and a cumulative amount are different measurements.
- Copying a dose from another strength: The same milligram dose requires different mL and unit calculations when concentration changes.
- Changing the dosing protocol to fit the container: A 50 mg strength affects yield and measurement, not the evidence behind an injection protocol.
- Applying topical guidance to an injectable protocol: Topical concentration and subcutaneous injection volume are not interchangeable.
A calculation check should identify the intended dose, confirm the 16.67 mg/mL concentration, calculate mL, convert mL to U-100 units, and then compare the result with the matching chart row. This page does not instruct a reader to inject GHK-Cu; it explains how a named research calculation is converted. When GHK-Cu is dosed in a research model, route and frequency must remain explicit. This sequence makes the peptide dosage transparent and reproducible.
GHK-Cu Peptide Use, Formulations, and Research Terms
GHK-Cu is a copper peptide, but search results often combine several different product types. The GHK peptide and its copper-bound complex are related terms, not interchangeable formulation labels. A 50mg GHK-Cu vial describes the contained mass; it does not establish a dose or route. Topical GHK-Cu products may be described as a cream, gel, topical serum, or cosmetic copper peptide. A GHK-Cu serum applied to skin is evaluated by concentration, delivery vehicle, and topical application area. GHK-Cu tablets, oral products, and injectable GHK-Cu preparations introduce different absorption, formulation, and evidence questions.
Research on GHK-Cu includes topical skin studies, collagen and elastin measurements, wound models, penetration studies, and laboratory work on GHK-Cu gene expression and matrix remodeling.[1][4][5][7][8] The effects of GHK-Cu reported in one formulation should not be transferred automatically to another. For example, a topical copper peptide finding does not establish an injectable dose, and a GHK-Cu topical dosage does not validate a subcutaneous dose.
GHK-Cu for skin and GHK-Cu hair research are common topics, but the cited human evidence is more developed for topical skin and wound-related endpoints than for a 50 mg injectable protocol. GHK-Cu may influence pathways relevant to tissue remodeling, yet those mechanistic observations remain separate from claims about visible results, a universal GHK-Cu timeline, or clinical effectiveness.[6][7]
GHK-Cu Side Effects and Research Monitoring
GHK-Cu side effects cannot be summarized from topical studies alone. An injectable dose introduces route-specific questions involving sterility, local reactions, formulation quality, systemic exposure, and copper-related biology. FDA compounding materials identify uncertainty and safety concerns relevant to injectable GHK-Cu.[10][11]
A research record should capture the peptide identifier, dose, concentration, route, injection site, timing, cycle length, preparation lot, and any observed reaction. Consistent documentation helps distinguish a measurement error from a formulation issue or an observed biological response. General injection-safety sources support sterile handling, site rotation, and sharps disposal; they do not establish a GHK-Cu dose.[15][16][17]
GHK-Cu 50 mg Dosage FAQ
How do you calculate the concentration of a 50 mg GHK-Cu vial?
Divide 50 mg by the 3.0 mL final volume. The result is approximately 16.67 mg/mL.
How much GHK-Cu is in one U-100 syringe unit?
At 16.67 mg/mL, one U-100 unit equals 0.01 mL and contains approximately 0.1667 mg, or 166.7 mcg.
Is a U-100 unit the same as a peptide IU?
No. On this page, U-100 units are syringe volume markings. The peptide amount is stated separately in milligrams or micrograms.
Does a 50 mg vial require a different GHK-Cu schedule?
Vial strength changes concentration, syringe volume, and vial yield. It does not independently determine the research schedule. The displayed schedule must be read together with the matching 3.0 mL final volume.
Can topical GHK-Cu research validate an injectable protocol?
No. Topical studies can inform compound and skin-research context, but route, formulation, exposure, and safety differ. Injectable calculations require their own evidence boundaries.
What should be checked before using the dosage chart?
Confirm that the vial contains 50 mg, the final volume is 3.0 mL, the syringe is U-100, and every chart row states the amount, units, mL, frequency, and phase. If any input differs, recalculate before interpreting the markings.
References
Research References
- 1Mulder GD, et al. Wound Repair and Regeneration. Human diabetic-ulcer study of topical glycyl-L-histidyl-L-lysine copper.
- 2Miller TR, et al. Archives of Facial Plastic Surgery. 2006. Topical copper tripeptide complex after carbon-dioxide laser resurfacing.
- 3Abdulghani AA, et al. 1998. Comparative topical-cream study including a copper-binding peptide preparation.
- 4Badenhorst T, et al. 2016. Split-face GHK-Cu nano-serum study of collagen, elastin, and wrinkle-related outcomes.
- 5Hostynek JJ, et al. Inflammation Research. 2010. Final human-skin penetration paper for a GHK-Cu preparation.
- 6Maquart FX, et al. Journal of Clinical Investigation. 1993. Local GHK-Cu exposure in a rat wound-chamber model.
- 7Pickart L, Margolina A. International Journal of Molecular Sciences. 2018. Review of regenerative and gene-expression research involving GHK-Cu.
- 8Maquart FX, et al. 2000. GHK-related modulation of matrix metalloproteinase-2 expression.
- 9ClinicalTrials.gov. NCT07437586. Ongoing Phase 2 study of topical GHK-Cu gel for acute skin-wound healing.
- 10U.S. Food and Drug Administration. Compounding safety-risk information that includes injectable GHK-Cu.
- 11U.S. Food and Drug Administration. 503A Categories Update. Route-specific bulk-substance evaluation context for GHK-Cu.
- 12U.S. Food and Drug Administration. 510(k) K953853. Iamin Gel topical wound-dressing device record.
Additional Technical and Protocol Sources
- 15Roswell Park Comprehensive Cancer Center. General self-injection preparation, site rotation, and disposal guidance.
- 16Centers for Disease Control and Prevention. Current subcutaneous injection technique job aid.
- 17World Health Organization, NCBI Bookshelf. Best practices for injections and related procedures.
Related research, protocols, and guides
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Research overview
Other vial-strength protocols
Related protocols and comparisons